8-K: Cardinal Health Exceeds Expectations, Raises Full-Year Outlook After Strong Q2

Cardinal Health reported a 4% revenue decrease in Q2 FY25, but a 16% increase excluding a large customer contract expiration, leading to an increased full-year earnings outlook.

Summary

• Cardinal Health's second quarter fiscal year 2025 revenue was $55.3 billion, a 4% decrease compared to the same period last year.
• However, excluding the impact of a large customer contract expiration, revenue increased by 16%.
• GAAP operating earnings were $549 million, while non-GAAP operating earnings increased by 9% to $635 million.
• GAAP diluted EPS was $1.65, and non-GAAP diluted EPS increased by 2% to $1.93.
• The company has raised its fiscal year 2025 non-GAAP EPS guidance to a range of $7.85 to $8.00, up from $7.75 to $7.90.
• Cardinal Health completed its acquisition of a 73% ownership stake in GI Alliance during the quarter.
• The Pharmaceutical and Specialty Solutions segment saw a 4% revenue decrease, but a 17% increase excluding the contract expiration.
• The Global Medical Products and Distribution segment revenue increased by 1% to $3.2 billion.
• The 'Other' segment revenue increased by 13% to $1.3 billion.
• The company updated its fiscal year 2025 guidance for Pharmaceutical and Specialty Solutions segment profit to 10% to 12% growth, from 4% to 6% growth.
• The company also updated its GMPD fiscal 2025 segment profit guidance to a range of $130 million to $150 million from the prior range of $140 million to $175 million.
• Interest and other expense guidance was updated to a range of $200 million to $230 million, from $140 million to $170 million.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with a revenue decrease but strong underlying growth and increased guidance. The strategic acquisitions and new product offerings are positive, but the risks and challenges are also significant. Overall, the sentiment is positive but with caution.

Positives

• The company's non-GAAP operating earnings and diluted EPS showed growth.
• The fiscal year 2025 non-GAAP EPS guidance was raised, indicating positive future expectations.
• The acquisition of GI Alliance and Integrated Oncology Network are expected to drive specialty growth.
• The Pharmaceutical and Specialty Solutions segment showed strong growth excluding the impact of the customer contract expiration.
• The company is expanding its capabilities in theranostics with the commercial production of actinium-225.
• The new distribution center in Fort Worth is expected to improve at-Home Solutions operations.
• Cardinal Health was named to Forbes 2025 Most Trusted Companies in America list.

Negatives

• Overall revenue decreased by 4% compared to the same quarter last year.
• The Global Medical Products and Distribution segment experienced a write-off of uncollectible receivables in the WaveMark business.
• Interest and other expense guidance was increased due to new debt financing and foregone interest income related to acquisitions.
• The GMPD segment profit guidance was lowered due to the write-off of uncollectible receivables.

Risks

• The company faces risks related to achieving strategic objectives, including the GMPD Improvement Plan.
• Competitive pressures in various lines of business could impact customer contracts.
• Uncertainties associated with the pricing of branded pharmaceuticals and potential legislative action pose a risk.
• Litigation matters, including a Department of Justice investigation, could have a negative impact.
• Events outside of the company's control, such as weather or geopolitical events, could impact demand or cause supply shortages.
• The performance of the generics program and the amount of generic deflation are risks.
• Recently completed and pending acquisitions carry risks, including entry into new lines of business.
• The at-Home reporting unit goodwill could become impaired due to changes in the long-term financial plan, interest rates, or tax rates.

Future Outlook

The company raised its fiscal year 2025 non-GAAP EPS guidance to $7.85 to $8.00, reflecting the impacts of the completed acquisitions of Integrated Oncology Network (ION) and its majority stake in GI Alliance. The company also updated its fiscal year 2025 guidance for Pharmaceutical and Specialty Solutions segment profit to 10% to 12% growth, and GMPD segment profit guidance to a range of $130 million to $150 million.

Management Comments

• We delivered strong second quarter financial results while taking significant strategic and operational actions to position us for future growth, said Jason Hollar, CEO of Cardinal Health.
• Led by robust demand across our Pharmaceutical and Specialty Solutions segment, we are again pleased to raise our fiscal 2025 enterprise guidance.
• We are also pleased to announce the closing of our acquisition of a majority position in GI Alliance. GI Alliance, along with our recently completed Integrated Oncology Network transaction in support of our Navista oncology platform, enables our continued specialty growth and delivers a greater value proposition for providers and patients.

Industry Context

This announcement reflects Cardinal Health's strategic focus on expanding its specialty solutions and oncology platforms, aligning with the broader industry trend of consolidation and growth in these areas. The acquisition of GI Alliance and ION positions Cardinal Health to capitalize on the increasing demand for specialized healthcare services.

Comparison to Industry Standards

• Cardinal Health's revenue decline of 4% is notable, but the 16% increase excluding the contract expiration suggests underlying strength. Comparatively, McKesson, a major competitor, has shown varied revenue growth in recent quarters, highlighting the impact of contract changes.
• The 9% increase in non-GAAP operating earnings is a positive sign, while AmerisourceBergen has also reported growth in adjusted operating income, indicating a positive trend in the pharmaceutical distribution sector.
• The raised EPS guidance to $7.85-$8.00 is a positive signal, while other companies like CVS Health have also provided positive guidance, reflecting a generally optimistic outlook for the healthcare sector.
• The acquisition of GI Alliance is a strategic move similar to other companies expanding into specialty areas, such as Optum's acquisitions in physician practices, indicating a trend towards integrated healthcare solutions.
• The commercial production of actinium-225 is a unique development, setting Cardinal Health apart from competitors who are not yet offering this isotope at commercial scale.

Legal Proceedings

• The company is subject to a Department of Justice investigation focused on potential violations of the Anti-Kickback Statute and False Claims Act.

Stakeholder Impact

• Shareholders will benefit from the increased EPS guidance and strategic growth initiatives.
• Employees may see opportunities for growth and development with the expansion of the company's operations.
• Customers will benefit from the expanded specialty solutions and improved distribution capabilities.
• Suppliers may see increased demand for their products and services.
• Creditors may see increased confidence in the company's financial stability.

Next Steps

• The company will continue to integrate GI Alliance and Integrated Oncology Network.
• The company will focus on the continued execution of the GMPD Improvement Plan.
• The company will continue to develop and expand its theranostics capabilities.
• The company will complete the construction of the new at-Home Solutions distribution center in Fort Worth, Texas.

Key Dates

Keywords

Pharmaceuticals, Specialty Solutions, Medical Products, Distribution, Healthcare, Acquisition, GI Alliance, Oncology, Theranostics, Actinium-225, Earnings, EPS, Guidance